JP2006515359A - プロアントシアニジンによる性的機能及び性器血管系の改善 - Google Patents
プロアントシアニジンによる性的機能及び性器血管系の改善 Download PDFInfo
- Publication number
- JP2006515359A JP2006515359A JP2006500275A JP2006500275A JP2006515359A JP 2006515359 A JP2006515359 A JP 2006515359A JP 2006500275 A JP2006500275 A JP 2006500275A JP 2006500275 A JP2006500275 A JP 2006500275A JP 2006515359 A JP2006515359 A JP 2006515359A
- Authority
- JP
- Japan
- Prior art keywords
- hormone
- nitric oxide
- component
- preparation
- sexual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920002770 condensed tannin Polymers 0.000 title claims abstract description 38
- 230000036299 sexual function Effects 0.000 title claims description 22
- 230000006872 improvement Effects 0.000 title claims description 6
- 210000004392 genitalia Anatomy 0.000 title description 9
- 210000005166 vasculature Anatomy 0.000 title description 4
- 229940088597 hormone Drugs 0.000 claims abstract description 44
- 239000005556 hormone Substances 0.000 claims abstract description 44
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract description 34
- 230000001568 sexual effect Effects 0.000 claims abstract description 31
- 239000003163 gonadal steroid hormone Substances 0.000 claims abstract description 14
- 239000004475 Arginine Substances 0.000 claims abstract description 13
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000002243 precursor Substances 0.000 claims abstract description 10
- 239000000758 substrate Substances 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 8
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims abstract description 6
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims abstract description 6
- 239000003054 catalyst Substances 0.000 claims abstract description 5
- 230000003511 endothelial effect Effects 0.000 claims abstract description 5
- 239000004615 ingredient Substances 0.000 claims abstract description 3
- 230000004936 stimulating effect Effects 0.000 claims abstract 5
- 230000015572 biosynthetic process Effects 0.000 claims abstract 2
- 238000003786 synthesis reaction Methods 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims description 23
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- 238000009472 formulation Methods 0.000 claims description 13
- 230000001965 increasing effect Effects 0.000 claims description 12
- 239000013589 supplement Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000002688 persistence Effects 0.000 claims 2
- 239000000021 stimulant Substances 0.000 claims 2
- 239000002269 analeptic agent Substances 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 abstract description 4
- 230000001548 androgenic effect Effects 0.000 abstract description 3
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 28
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 23
- 235000018192 pine bark supplement Nutrition 0.000 description 22
- 229940106796 pycnogenol Drugs 0.000 description 22
- SUUWYOYAXFUOLX-ZBRNBAAYSA-N (2s)-2-aminobutanedioic acid;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CCCN=C(N)N SUUWYOYAXFUOLX-ZBRNBAAYSA-N 0.000 description 19
- 239000000284 extract Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 229960003604 testosterone Drugs 0.000 description 14
- 208000010228 Erectile Dysfunction Diseases 0.000 description 12
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 12
- 229930064664 L-arginine Natural products 0.000 description 12
- 235000014852 L-arginine Nutrition 0.000 description 12
- 201000001881 impotence Diseases 0.000 description 12
- 229960003310 sildenafil Drugs 0.000 description 11
- 235000009697 arginine Nutrition 0.000 description 9
- 229960003121 arginine Drugs 0.000 description 9
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 8
- 229920001991 Proanthocyanidin Polymers 0.000 description 8
- 239000003098 androgen Substances 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 6
- 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 5
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 5
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 5
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000001850 reproductive effect Effects 0.000 description 5
- CXQWRCVTCMQVQX-LSDHHAIUSA-N (+)-taxifolin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-LSDHHAIUSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 4
- 230000009986 erectile function Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229940106587 pine bark extract Drugs 0.000 description 4
- 229920002414 procyanidin Polymers 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 3
- 229960002223 arginine aspartate Drugs 0.000 description 3
- 235000005487 catechin Nutrition 0.000 description 3
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 3
- 229950001002 cianidanol Drugs 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 3
- 230000001856 erectile effect Effects 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 235000020741 pine bark extract Nutrition 0.000 description 3
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 3
- 230000007103 stamina Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 2
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- CZWCKYRVOZZJNM-UHFFFAOYSA-N Prasterone sodium sulfate Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 CZWCKYRVOZZJNM-UHFFFAOYSA-N 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000037007 arousal Effects 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000004456 color vision Effects 0.000 description 2
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- KQNGHARGJDXHKF-UHFFFAOYSA-N dihydrotamarixetin Natural products C1=C(O)C(OC)=CC=C1C1C(O)C(=O)C2=C(O)C=C(O)C=C2O1 KQNGHARGJDXHKF-UHFFFAOYSA-N 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 235000012734 epicatechin Nutrition 0.000 description 2
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 2
- 235000020650 eye health related herbal supplements Nutrition 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 210000003899 penis Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 229960002847 prasterone Drugs 0.000 description 2
- 229950009829 prasterone sulfate Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 231100000872 sexual dysfunction Toxicity 0.000 description 2
- 230000036332 sexual response Effects 0.000 description 2
- 229960002639 sildenafil citrate Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 1
- 206010002261 Androgen deficiency Diseases 0.000 description 1
- QADHLRWLCPCEKT-UHFFFAOYSA-N Androstenediol Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)O)C4C3CC=C21 QADHLRWLCPCEKT-UHFFFAOYSA-N 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000021663 Female sexual arousal disease Diseases 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 241001236212 Pinus pinaster Species 0.000 description 1
- 235000005105 Pinus pinaster Nutrition 0.000 description 1
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 1
- 229930182448 Prodelphinidin Natural products 0.000 description 1
- 229920000124 Prodelphinidin Polymers 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
- QADHLRWLCPCEKT-LOVVWNRFSA-N androst-5-ene-3beta,17beta-diol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC=C21 QADHLRWLCPCEKT-LOVVWNRFSA-N 0.000 description 1
- 229950009148 androstenediol Drugs 0.000 description 1
- 229960005471 androstenedione Drugs 0.000 description 1
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 1
- 230000003222 cGMP degradation Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- -1 fall Chemical compound 0.000 description 1
- QOLIPNRNLBQTAU-UHFFFAOYSA-N flavan Chemical class C1CC2=CC=CC=C2OC1C1=CC=CC=C1 QOLIPNRNLBQTAU-UHFFFAOYSA-N 0.000 description 1
- 150000002206 flavan-3-ols Chemical class 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035936 sexual power Effects 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960000746 testosterone undecanoate Drugs 0.000 description 1
- UDSFVOAUHKGBEK-CNQKSJKFSA-N testosterone undecanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)CC2 UDSFVOAUHKGBEK-CNQKSJKFSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000006438 vascular health Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940094720 viagra Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
本発明は、プロアントシアニジン源、アルギニン源、あるいはホルモン補給剤を含む成分を用いて、男女の性的適応度又は機能と、性器血管系(sexual vascular system)の健康を改善することに関する。プロアントシアニジン源は、植物の抽出物であり、アルギニン源は、アルギニンアスパルテート(arginine aspartate)に由来する。ホルモン補給剤は、ホルモンそれ自体、ホルモン前駆体、ホルモン産生促進剤又はホルモンの生物学的利用能を高めるエンハンサー(hormone bioavailability enhancer)であってよい。成分の全部又は一部は、組成物の一部であるか、及び/又はキット内で互いに分離している。
男性は20歳台前半のときに、性的能力がピークにあると考えられている。一方、年を経るにつれて、身体の生体組織が変化し、性的スタミナ、性的能力の他に、性的楽しみさえ低下し始めることに気付くであろう。性の営みを行なう気になるために、少しの努力を必要とし始めるであろう。
本発明の一態様は、男女とも、服用によって、性的な反応、持久力及び快楽を、持続及び維持するための安全で自然的な方法を提供できる生成物である。それは、具体的には、プロアントシアニジンとアルギニン源である基質の配合物(blend)、望ましくは、L−アルギニンとアルギニンアスパルテートなどのアスパラギン酸の塩又はジペプチドの配合物である製剤(preparation)を含んでいる。前記配合物を投与すると、内皮型NO−シンターゼは、プロアントシアニジンによって刺激される。刺激された内皮型NO−シンターゼ酵素は、基質から一酸化窒素を合成するための触媒として作用し、その結果、一酸化窒素は、基質から放出される。アルギニン源とプロアントシアニジンは、治療的に有効量を投与することによって、十分な量の一酸化窒素が合成され放出されるので、毎日の投与を所定期間行なうと、所定期間終了までに、性的適応度(sexual fitness)又は機能が改善される。なお、アンドロゲンホルモンの欠乏を解消させて、性的興奮及び欲求を増加又は復活させることができるように、前記配合物には、テストステロン又はデヒドロエピアンドロステロンを含めることができる。
本発明は、アルギニン(例えばL−アルギニン)源とプロアントシアニジン源との配合物を長期間使用することに関する。アルギニンの源は、アルギニン及びアスパラギン酸の塩又はペプチド、例えばアルギニンアスパルテートが好ましい。プロアントシアニジンの源は、ピクノジェノール(登録商標)又は他のプロアントシアニジン含有抽出物であることが好ましい。
1.弱い(Weakened):陰茎は大きくなり、ある程度堅くなるが、膣に挿入するには不十分である。
2.時間がかかる(Delayed):勃起するが、挿入するには不十分であり、さらに、通常よりも多くの時間を要する。
3.行為困難(Hesitating):接触の前後において、勃起が不安定であり、性交が困難である。
4.行為不能(Loosing):愛撫中は勃起するが、挿入しようとした時又は性交中に萎える。
また、試験中、副作用は観察されなかった。被験者からは、過剰刺激の報告はなく、陰茎持続勃起症は観察されなかった。
Claims (18)
- 性的機能を改善するための製剤であって、
一酸化窒素を生成するためのアルギニン源としての基質と、
一酸化窒素を合成するための触媒として作用するプロアントシアニジンを、内皮型NO−シンターゼ酵素を刺激することのできる量を含有する刺激剤と、
を構成成分として含んでおり、
前記構成成分は、治療のために、所定期間に亘って少なくとも毎日投与すると、十分な量の一酸化窒素が合成されて放出され、所定期間の終了までに性的機能を改善させるのに有効な量である製剤。 - 構成成分は配合されて一の組成物を構成することを特徴とする請求項1に記載の製剤。
- 請求項1の製剤が入れられた容器であることを特徴とするキット。
- 容器内に少なくともホルモン補給剤を含むことをさらに特徴としており、該ホルモン補給剤は、血液中のホルモンの濃度を高める作用を有するホルモン濃度上昇剤と、ホルモンの産生を刺激する作用を有するホルモン産生刺激剤と、ホルモン前駆体とから成る群から選択される請求項3に記載のキット。
- 容器内に少なくとも一種のホルモン補給剤を含むことをさらに特徴としており、該ホルモン補給剤は、生物学的利用能をより向上させるために、フリーホルモンの割合を増加させる作用を有する請求項3に記載のキット。
- 容器内に少なくとも一種のホルモン補給剤を含むことをさらに特徴としており、該ホルモン補給剤は、性ホルモンと、性ホルモン前駆体と、性ホルモン産生を刺激し、性ホルモンの生物学的利用能を向上させる作用を有する刺激剤とから成る群から選択される構成成分を含んでいる請求項3に記載のキット。
- 基質と刺激剤は組成物の一部であることを特徴とする請求項3に記載のキット。
- 構成成分は容器内で互いに分離し区別されていることを特徴とする請求項3に記載のキット。
- 一酸化窒素シンターゼ酵素を刺激し、一酸化窒素を放出することによって性的機能を高める薬物を生産するために、製剤を所定期間に亘って毎日投与することを特徴とする製剤の使用であって、前記製剤は、基質と刺激剤を構成成分として含有し、前記基質は、一酸化窒素を生成するためのアルギニン源であり、前記刺激剤は、内皮型NO−シンターゼ酵素を刺激するために、一酸化窒素を合成するための触媒として作用するプロアントシアニジンを含んでおり、前記構成成分は、所定期間の終了までに性的機能を改善させるのに十分な量の一酸化窒素を合成し、該一酸化窒素の放出を引き起こすのに十分な量である、製剤の使用。
- 製剤は、昂進用の成分と持続用の成分を含んでおり、昂進用成分の含有量は、持続用成分よりも多く、性的機能の改善は、昂進用成分を毎日投与することにより、所定期間の終了までに達成され、その後、改善された性的機能は、持続用成分を毎日投与することによって維持されることを特徴とする請求項9の使用。
- 製剤は、血液中のホルモンの濃度を高めるホルモン濃度上昇剤と、ホルモンの産生を刺激するホルモン産生刺激剤と、ホルモン前駆体とから成る群から選択されるホルモン補給剤を含むこをと特徴とする請求項9の使用。
- 製剤は、生物学的利用能をより向上させるために、フリーホルモンの割合を増加させる少なくとも一種のホルモン補給剤を含むことを特徴とする請求項9の使用。
- 製剤は、性ホルモンと、性ホルモン前駆体と、性ホルモン産生を刺激し、性ホルモンの生物学的利用能を向上させる作用を有する刺激剤と、から成る群から選択されるものを構成成分として有するホルモン補給剤を含むことを特徴とする請求項9の使用。
- 構成成分は配合されて一の組成物を構成することを特徴とする請求項9の使用。
- 構成成分は互いに分離し区別されていることを特徴とする請求項9の使用。
- 請求項1の製剤を商業広告することを特徴とする請求項1の製剤の普及促進方法。
- 広告は、製剤が性的機能を改善すること又は性的適応度を向上させることを含むことを特徴とする請求項16の方法。
- 広告は、製剤が毎日投与されることを推奨することを含むことを特徴とする請求項16の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43973703P | 2003-01-13 | 2003-01-13 | |
US60/439,737 | 2003-01-13 | ||
US10/685,677 | 2003-10-15 | ||
US10/685,677 US20040137081A1 (en) | 2003-01-13 | 2003-10-15 | Attaining sexual wellness and health of the sexual vascular system with proanthocyanidins |
PCT/IB2004/000019 WO2004062680A1 (en) | 2003-01-13 | 2004-01-08 | Attaining sexual wellness and health of the sexual vascular system with proanthocyanidins |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011170970A Division JP5602696B2 (ja) | 2003-01-13 | 2011-08-04 | プロアントシアニジンによる性的機能及び性器血管系の改善 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006515359A true JP2006515359A (ja) | 2006-05-25 |
JP5457624B2 JP5457624B2 (ja) | 2014-04-02 |
Family
ID=32718110
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006500275A Expired - Lifetime JP5457624B2 (ja) | 2003-01-13 | 2004-01-08 | プロアントシアニジンによる性的機能及び性器血管系の改善 |
JP2011170970A Expired - Lifetime JP5602696B2 (ja) | 2003-01-13 | 2011-08-04 | プロアントシアニジンによる性的機能及び性器血管系の改善 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011170970A Expired - Lifetime JP5602696B2 (ja) | 2003-01-13 | 2011-08-04 | プロアントシアニジンによる性的機能及び性器血管系の改善 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1587522B1 (ja) |
JP (2) | JP5457624B2 (ja) |
AT (1) | ATE409472T1 (ja) |
AU (1) | AU2004204527B2 (ja) |
CA (1) | CA2513129A1 (ja) |
DE (1) | DE602004016820D1 (ja) |
HK (1) | HK1079112A1 (ja) |
MY (1) | MY139231A (ja) |
TW (1) | TWI330529B (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012041296A (ja) * | 2010-08-19 | 2012-03-01 | Medience Corp | 血管内皮機能改善剤、一酸化窒素産生促進剤、及び飲食品 |
JP2013530985A (ja) * | 2010-06-25 | 2013-08-01 | ホーファグ リサーチ (アイピー) ピーアールイー リミテッド | セクシャルウェルネスを改善するための組成物 |
JP2020164495A (ja) * | 2019-03-29 | 2020-10-08 | 株式会社東洋新薬 | 男性活力用組成物及び組成物 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2314771A (en) * | 1996-07-02 | 1998-01-14 | Multimed Ltd | Topical preparation for relief of erectile dysfunction |
GB2341771A (en) * | 1998-09-18 | 2000-03-22 | Pixelfusion Ltd | Address decoding |
WO2001089543A2 (en) * | 2000-05-26 | 2001-11-29 | Horphag Research Limited | Use of proanthocyanidins as an active ingredient of a stimulator and l-arginine or its salts as a source of nitric oxide to relieve symptoms of erectile dysfuntion |
JP2002193809A (ja) * | 2000-11-30 | 2002-07-10 | Pfizer Prod Inc | 男性更年期を処置するための方法 |
JP2002539163A (ja) * | 1999-03-16 | 2002-11-19 | ペンテツク・フアーマシユーテイカルズ・インコーポレイテツド | アポモルフィン及びシルデナフィル組成物 |
-
2004
- 2004-01-05 TW TW093100147A patent/TWI330529B/zh not_active IP Right Cessation
- 2004-01-08 DE DE602004016820T patent/DE602004016820D1/de not_active Expired - Fee Related
- 2004-01-08 AU AU2004204527A patent/AU2004204527B2/en not_active Ceased
- 2004-01-08 AT AT04700741T patent/ATE409472T1/de not_active IP Right Cessation
- 2004-01-08 CA CA002513129A patent/CA2513129A1/en not_active Abandoned
- 2004-01-08 EP EP04700741A patent/EP1587522B1/en not_active Expired - Lifetime
- 2004-01-08 JP JP2006500275A patent/JP5457624B2/ja not_active Expired - Lifetime
- 2004-01-09 MY MYPI20040058A patent/MY139231A/en unknown
-
2005
- 2005-12-09 HK HK05111305.2A patent/HK1079112A1/xx not_active IP Right Cessation
-
2011
- 2011-08-04 JP JP2011170970A patent/JP5602696B2/ja not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2314771A (en) * | 1996-07-02 | 1998-01-14 | Multimed Ltd | Topical preparation for relief of erectile dysfunction |
GB2341771A (en) * | 1998-09-18 | 2000-03-22 | Pixelfusion Ltd | Address decoding |
JP2002539163A (ja) * | 1999-03-16 | 2002-11-19 | ペンテツク・フアーマシユーテイカルズ・インコーポレイテツド | アポモルフィン及びシルデナフィル組成物 |
WO2001089543A2 (en) * | 2000-05-26 | 2001-11-29 | Horphag Research Limited | Use of proanthocyanidins as an active ingredient of a stimulator and l-arginine or its salts as a source of nitric oxide to relieve symptoms of erectile dysfuntion |
JP2002193809A (ja) * | 2000-11-30 | 2002-07-10 | Pfizer Prod Inc | 男性更年期を処置するための方法 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013530985A (ja) * | 2010-06-25 | 2013-08-01 | ホーファグ リサーチ (アイピー) ピーアールイー リミテッド | セクシャルウェルネスを改善するための組成物 |
JP2012041296A (ja) * | 2010-08-19 | 2012-03-01 | Medience Corp | 血管内皮機能改善剤、一酸化窒素産生促進剤、及び飲食品 |
JP2020164495A (ja) * | 2019-03-29 | 2020-10-08 | 株式会社東洋新薬 | 男性活力用組成物及び組成物 |
Also Published As
Publication number | Publication date |
---|---|
AU2004204527B2 (en) | 2008-09-04 |
TWI330529B (en) | 2010-09-21 |
DE602004016820D1 (de) | 2008-11-13 |
TW200509901A (en) | 2005-03-16 |
CA2513129A1 (en) | 2004-07-29 |
HK1079112A1 (en) | 2006-03-31 |
JP5457624B2 (ja) | 2014-04-02 |
ATE409472T1 (de) | 2008-10-15 |
EP1587522A1 (en) | 2005-10-26 |
AU2004204527A1 (en) | 2004-07-29 |
EP1587522B1 (en) | 2008-10-01 |
JP2012006948A (ja) | 2012-01-12 |
MY139231A (en) | 2009-09-30 |
JP5602696B2 (ja) | 2014-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7989007B2 (en) | Weight loss composition | |
US9028890B2 (en) | Composition for improving sexual wellness | |
US6368640B1 (en) | Method and composition for improving sexual fitness | |
CA2260892A1 (en) | Appetite suppression | |
WO2006002096A2 (en) | Low doses of l-citrulline for treating diseases | |
JP7459099B2 (ja) | 性機能を改善するための組成物 | |
JP2003534286A (ja) | 勃起障害症状改善のために、刺激物質の活性成分としてプロアントシアニジン、一酸化窒素源としてlアルギニン又はその塩の使用 | |
JP5602696B2 (ja) | プロアントシアニジンによる性的機能及び性器血管系の改善 | |
US20040137081A1 (en) | Attaining sexual wellness and health of the sexual vascular system with proanthocyanidins | |
IsHak et al. | Sex and natural sexual enhancement: Sexual techniques, aphrodisiac foods, and nutraceuticals | |
WO1999008681A1 (en) | Inducing neurotransmitter and neuropeptide activity | |
WO2012063198A1 (en) | Compositions for the prevention and treatment of erectile dysfunction and impotence and for improving sport performance | |
US20050171030A1 (en) | Relieving symptoms of erectile dysfunction and attaining sexual wellness and health of the sexual vascular system with proanthocyanidins | |
US7371415B1 (en) | Method and composition for improving sexual fitness | |
EP3027064B1 (fr) | Composition pharmaceutique, diététique ou alimentaire liquide ou semi-liquide dépourvue d'amertume contenant un sel d'arginine | |
JP2022552311A (ja) | 改善した二日酔い止め組成物、その調製及び使用 | |
EA045187B1 (ru) | Композиции для улучшения сексуальной функции | |
US20240307476A1 (en) | Powdered food supplement for producing a beverage | |
FR2989557A1 (fr) | Nouvelles compositions alimentaires et leur mode de realisation | |
WO2018070971A1 (ru) | Фармацевтическая композиция в форме оромукозного спрея для лечения эректильной дисфункции и легочной артериальной гипертензии | |
JP2009256364A (ja) | 動物のオスおよびメス、およびヒトにおける受精能の健康状態を改善するための方法および組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090526 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20090819 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090825 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090819 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090925 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091125 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100209 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100510 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20101224 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110405 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110905 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110905 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130925 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140110 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5457624 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |